Grade: Pharmaceutical Grade

Factory Location: Shandong

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Monthly Production Capacity: 100kg

Contract Manufacturing: CRO,CMO

Packaging Information: 5kg/drum

Delivery Lead Time: 15days

Sample Provided: yes

Payment Terms: T/T

Products details

Abemaciclib is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. It is used for the treatment of advanced or metastatic breast cancers.

Application&Function

Abemaciclib is a CD4/6 kinase inhibitor. This type of kinase is activated by connecting D-cyclin. In breast cancer cell lines that are estrogen receptor positive (HR+), cyclin D1 and CD4/ 6 It can bind to phosphorylation of retinoblastoma protein (Rb), cell cycle progression and cell proliferation. In vitro, continuous exposure to Abemaciclib inhibits Rb phosphorylation and prevents entry from G1 into the S phase of the cell cycle, leading to cell senescence and apoptosis. In breast cancer xenotransplantation models, Abemaciclib monotherapy or combined with anti-estrogens can be administered continuously every day to shrink tumors.